Selling GlycoMark

1
Selling GlycoMark
2
Selling GlycoMark Elevator

• Doctor ___, you may be aware that the UKPDS
  study showed every 1 decrease in hemoglobin A1c
  reduces risk of cardiovascular disease by 14.

3
Selling GlycoMark - Elevator

• Its obviously important to take advantage of
  HbA1c values so that you can help your patients.
  However, you may not be aware that HbA1c values
  can be misleading.

4
Selling GlycoMark - Elevator

• Unfortunately, some patients in the near
  normal HbA1c range actually are not in good
  glycemic control and remain at a high risk of
  multiple complications of diabetes.

5
Selling GlycoMark

• If you have the physicians interest some or all
  of the following words and information may be
  useful

6
Selling GlycoMark

• My company ____________ has identified GlycoMark
  as the most significant new blood test for
  effective diabetes control and treatment.
  GlycoMark responds more rapidly than other
  diabetes markers to changes in hyperglycemia and
  can be used with hemoglobin A1c to determine what
  patients are, in fact, in glycemic control.
  Furthermore, GlycoMark has been found to be the
  most accurate test for drug efficacy

7
Selling GlycoMark

• Many studies indicate that lowering HbA1c from
  8.5 to below 6.5 can have a profound effect on
  lowering risks of cardiovascular disease,
  retinopathy, neuropathy and nephropathy and save
  lives.

8
Selling GlycoMark

• Only GlycoMark, an assay of 1,5-anhydro-D-glucito
  l, can accurately tell you that your patients
  glycemia is, in fact, under control.

9
Selling GlycoMark

• GlycoMark uniquely reflects all post-meal
  hyperglycemia over a 1 2 week time frame.
  Hemoglobin A1c and fructosamine average hypo- and
  hyperglycemia over 2 3 months and 2 3 weeks,
  respectively.

10
Selling GlycoMark

• Due to this averaging, HbA1c values in the
  supposed near normal ranges, 6.5 to 8.5, may
  actually have abnormally high and frequent
  post-meal glycemic excursions. Studies indicate
  that a significant number of your patients in
  this near normal HbA1c range are actually not in
  glycemic control.

11
Selling GlycoMark

• A recent study showed that two patients
  undergoing CGMS had similar near normal
  hemoglobin A1c levels (approximately 7.4)
  however, one of these individuals had frequent
  and high post meal blood glucose spikes.
  GlycoMark was able to differentiate these
  patients.
• Dungan K. et al. 2006. 1,5-anhydoglucitol and
  postprandial hyperglycemia as measured by
  continuous glucose monitoring system in
  moderately controlled patients with diabetes.
  Diabetes Care 296 1214 1219.
• CGMS is continuous glucose monitoring system

12
Selling GlycoMark

• Pharmaceutical companies use GlycoMark to show
  the efficacy of their anti-hyperglycemic drugs
  such as sitagliptin, exenatide and pramlintide.
  Only GlycoMark reflects significant improvement
  in post meal hyperglycemia in all of these
  clinical trials and may also be useful in
  regulating dosage.

13
Selling GlycoMark

• GlycoMark is FDA approved and is now in the IDF
  guidelines for diabetes care.

14
Selling GlycoMark

• GlycoMark is the most effective way to manage
  both post-meal hyperglycemia and
  anti-hyperglycemic drug therapy.

15
Selling GlycoMark

• GlycoMark is easy to use, requires a single
  standard blood draw that can be taken at any
  time. It is reimbursable by Medicare and most
  private insurers.

16
Changing Behavior

• Promote GlycoMark as an adjunct test to HbA1c in
  order to effectively lower risks of
  cardiovascular, retinopathy, neuropathy,
  nephropathy, etc. .
• GlycoMark should be promoted as an adjunct to
  hemoglobin A1c for monitoring post meal
  hyperglycemia in moderately controlled patients.
  Once hemoglobin A1c has identified patients in
  the near normal range of 6.5 to 8.5, GlycoMark
  is used to differentiate patients who are in true
  compliance.
• Only GlycoMark can effectively reflect
  anti-hyperglycemic drug efficacy.
• GlycoMark can also be promoted as a better test
  than either hemoglobin A1c or fructosamine
  because it uniquely reflects hyperglycemia over 1
  2 weeks. Endocrinologists will grasp this
  quickly. Try to focus on PPG control and
  lowering risks when presenting GlycoMark to
  primary care physicians.

17
Changing Behavior

• Try to get the doctor to test some of his
  patients (recommend a ten patients study) using
  HbA1c and GlycoMark to differentiate patients who
  are not in control. He should find that at least
  25 of these patients will not be in proper
  control.
• GlycoMark can be tested using either serum (red
  top or gel barrier) or EDTA plasma (lavender
  top). One ml of sample is recommended.

18
GlycoMark

• Seldom are tests introduced with such
  significant benefits for patients, physicians,
  the healthcare system.
• You will find the recognition of GlycoMark
  among physicians, especially endocrinologists, is
  already high. This should facilitate your sales
  and provide an entry to new accounts.
• Follow-up is essential to see how they are using
  GlycoMark to help their diabetic patients better
  manage their disease.